$ATRA

NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.

Moderna appointed Juan Andres as its new COO to support expansion into oncology. Pierre Fabre and Atara refiled Ebvallo for FDA approval to treat a rare blood cancer. Beam Therapeutics sued a Chinese company, alleging IP theft by a former scientist.

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.

Cherry Brian N purchased 104,166 shares of Atara Biotherapeutics, Inc. (ATRA) at $9.60 ($1.00M total) on 2026-09-04.

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87%

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001604464 false 0001604464 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001604464 0001604464 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Atara Biotherapeutics (ATRA) filed a Form 144 SEC notice detailing the settlement of 13,887 vested Restricted Stock Units (RSUs) on May 15, 2026, under an S-8 registration plan, representing equity compensation. The filing also notes a previous sale of 2,996 shares on March 2, 2026, with associated proceeds of $15,237.36. This indicates routine equity compensation activity rather than discretionary open-market sales.

James Huang, a director and ten percent owner of Atara Biotherapeutics, Inc., along with Panacea Innovation Ltd., sold 313,446 shares of common stock totaling $3,165,020 on May 7, 2026, at an average price of $10.0975 per share. This sale follows significant stock volatility and comes as InvestingPro analysis suggests the stock is overvalued. Meanwhile, Atara Biotherapeutics is actively working with Pierre Fabre Pharmaceuticals to advance the resubmission of the biologics license application for tabelecleucel, having received positive guidance from the FDA regarding study design.